GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Common Stock

Galapagos NV (BSP:G1LP34) Common Stock : R$1,830 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Galapagos NV Common Stock?

Galapagos NV's quarterly common stock increased from Sep. 2024 (R$1,807 Mil) to Dec. 2024 (R$1,878 Mil) but then declined from Dec. 2024 (R$1,878 Mil) to Mar. 2025 (R$1,830 Mil).

Galapagos NV's annual common stock declined from Dec. 2022 (R$1,631 Mil) to Dec. 2023 (R$1,571 Mil) but then increased from Dec. 2023 (R$1,571 Mil) to Dec. 2024 (R$1,878 Mil).


Galapagos NV Common Stock Historical Data

The historical data trend for Galapagos NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Common Stock Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,823.25 1,866.28 1,631.43 1,570.59 1,877.81

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,591.03 1,704.17 1,806.62 1,877.81 1,829.75

Galapagos NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Galapagos NV Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

No Headlines